The 44 rating InvestorsObserver gives to LogicBio Therapeutics Inc (LOGC) stock puts it near the top of the Healthcare sector.
In addition to scoring higher than 50 percent of stocks in the Healthcare sector, LOGC’s 44 overall rating means the stock scores better than 44 of all stocks.
Click Here to get the full Stock Score Report on LogicBio Therapeutics Inc (LOGC) Stock.
What do These Ratings Mean?
Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 44 means the stock is more attractive than 44 percent of stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style.
Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With LogicBio Therapeutics Inc Stock Today?
LogicBio Therapeutics Inc (LOGC) stock has risen 13.03% while the S&P 500 has fallen -1.18% as of 12:19 PM on Monday, Jan 27. LOGC is up $1.13 from the previous closing price of $8.67 on volume of 213,248 shares. Over the past year the S&P 500 has gained 23.18% while LOGC is up 19.22%. LOGC lost -$2.49 per share the over the last 12 months.
